Texas Oncology - Baylor Cancer Center
Welcome,         Profile    Billing    Logout  
 19 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
O'Shaughnessy, Joyce
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
06/25
12/25
NCT03193853: TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Completed
2
12
US
Tak-228 & Tak-117, Cisplatin & Nab Paclitaxel
Joyce O'Shaughnessy, Takeda
Triple Negative Breast Cancer
03/20
12/22
ExIST, NCT04032080: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Completed
2
10
US
Drug 1: LY3023414; Drug 2: Prexasertib
Baylor Research Institute, Eli Lilly and Company
Triple Negative Breast Cancer
06/22
11/22
NCT05113966: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Checkmark Data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Data from P2 trial for locally advanced or metastatic TNBC
Checkmark Presentation of data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Presentation of data from P2 trial for locally advanced or metastatic TNBC
Terminated
2
30
US
Trilaciclib, G1T28, CDK 4/6 inhibitor, Sacituzumab Govitecan-hziy, Trodelvy, IMMU-132
G1 Therapeutics, Inc.
Triple Negative Breast Cancer
11/23
06/24
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
NCT02187991: Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Completed
2
169
US
Paclitaxel, Taxol, Abraxane, Alisertib, MLN8237
US Oncology Research, Millennium Pharmaceuticals, Inc.
Breast Cancer, Breast Carcinoma, Breast Tumors, Malignant Neoplasm of Breast
04/24
08/24
NCT06517212: Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Recruiting
2
48
US
Tirzepatide, ZepBound
Baylor Research Institute
Breast Cancer, Breast Neoplasms, Breast Cancers
08/29
12/30
CA225200, NCT00248287: PhII ICb With/Without Erbitux in MBC Pts

Active, not recruiting
2
154
US
Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux
US Oncology Research, Bristol-Myers Squibb, Pfizer
Metastatic Breast Cancer
12/25
12/26
NCT05748834: Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Recruiting
2
36
US
Tucatinib, Tukysa, Doxil, doxorubicin hydrochloride liposome injection
SCRI Development Innovations, LLC, Seagen Inc.
Breast Cancer
07/26
07/26
ST101-101, NCT04478279 / 2019-004213-13: A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
125
Europe, US
ST101, Temozolomide, Radiation
Sapience Therapeutics
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
12/24
12/25
NCT03379428: Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Active, not recruiting
1/2
34
US
Trastuzumab, Herceptin, Ibrutinib 560 mg, Imbruvica, PCI-32765, Ibrutinib 840 mg, Ibrutinib 420 mg
US Oncology Research, AbbVie, Pharmacyclics LLC.
Breast Neoplasms, Malignant Neoplasm of Breast
01/25
01/25
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
NCT04265872: Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Recruiting
1
20
US
Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis, Keytruda, Velcade, Platinol
Baylor Research Institute
Breast Cancer
10/24
12/24
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
STU-2021-0657, NCT05029999: CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting
1
30
US
PLD Chemotherapy, Pegylated liposomal doxorubicin, CDX-1140, CD40 monoclonal antibody, CDX-301, Flt3 Ligand
University of Texas Southwestern Medical Center, Celldex Therapeutics, Gateway for Cancer Research
HER2-negative Breast Cancer, Metastatic Breast Cancer
04/25
04/25
NCT06008275: Neratinib in Combination With Ruxolitinib in Patients With mTNBC

Recruiting
1
20
US
Neratinib Oral Tablet, Ruxolitinib Oral Tablet, Jakafi
Baylor Research Institute
Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
06/26
12/26
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37

Download Options